A Review on Liposomal Drug Delivery in Cancer Therapy

A promising approach to cancer treatment, liposomal drug delivery systems provide better pharmacokinetics, more precise tumor targeting, and less systemic toxicity—the lipid bilayer spherical vesicles known as liposomes are both hydrophilic and hydrophobic. Due to the increased permeability and retention (EPR) effect, liposomes raise the concentration of anti-cancer medications in tumor tissues. Clinical approval has been granted to certain liposomal formulations, such as Doxorubicin, which are superior to non-liposomal forms. PEGylation and ligand attachment, two modifications to liposomal surfaces, have enhanced targeting and circulatory sustenance. Additionally, the tumor microenvironment can control drug release thanks to the combination of sensitive stimulation systems. Nevertheless, biological barriers, liposome stability, overcoming further biological obstacles, and bulk manufacturing optimization are still problems. Research and clinical work are needed to take full advantage of liposomal systems in cancer therapy.